Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo.
Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.